Having trouble accessing articles? Reset your cache.

Cerulean's CRLX101 misses OS endpoint in NSCLC trial

Cerulean Pharma Inc. (Cambridge, Mass.) said CRLX101 given every other week plus best supportive care missed

Read the full 162 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE